Literature DB >> 17986857

Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis.

Tao Ren1, Zhen-Ke Wen, Zhong-Min Liu, Yong-Jie Liang, Zhong-Liang Guo, Lin Xu.   

Abstract

CpG-oligonucleotides (CpG-ODN), which induce signaling through Toll-like receptor 9 (TLR9), are widely used as adjuvants in therapy against cancer. However, tumor cells express functional TLR9 were recently reported and the immune effect of CpG ODN on tumor cells remains unclear. Here we investigated the direct effects of CpG ODN on human tumor cell line 95D cells using flow cytometric analysis and Western blotting. We found strongly high expression of TLR9 in 95D cells. Stimulation of 95D cells with CpG ODN induced significantly elevated secretion of IL-1alpha and IL-8, as well as the expression of CXCR4, ICAM-1 and MMP-2. Furthermore, the invasion of 95D cells and TLR9 modifying 95C cells were significantly enhanced by stimulation of CpG ODN, which could be abrogated by inhibitory CpG ODN and chloroquine. These results suggest that functionally active TLR9 is expressed on human tumor cell lines, and may represent a novel insight on the role of TIL9 agonist used in tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17986857     DOI: 10.4161/cbt.6.11.4826

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  35 in total

1.  Autophagic activity measured in whole rat hepatocytes as the accumulation of a novel BHMT fragment (p10), generated in amphisomes by the asparaginyl proteinase, legumain.

Authors:  Anders Øverbye; Frank Sætre; Linda Korseberg Hagen; Harald Thidemann Johansen; Per O Seglen
Journal:  Autophagy       Date:  2011-09-01       Impact factor: 16.016

2.  Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer.

Authors:  Arja Jukkola-Vuorinen; Eeva Rahko; Katri S Vuopala; Renee Desmond; Petri P Lehenkari; Kevin W Harris; Katri S Selander
Journal:  J Innate Immun       Date:  2008-08-28       Impact factor: 7.349

Review 3.  Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?

Authors:  Li Yu; Liantang Wang; Shangwu Chen
Journal:  Cell Mol Life Sci       Date:  2011-11-03       Impact factor: 9.261

Review 4.  The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.

Authors:  Lei Wu; Lili Yang
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

5.  Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion.

Authors:  Huan Yang; Huiqin Zhou; Ping Feng; Xiaoni Zhou; Huiyan Wen; Xiaofang Xie; Haiying Shen; Xueming Zhu
Journal:  J Exp Clin Cancer Res       Date:  2010-07-10

6.  TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients.

Authors:  Chao Wang; Shouqiang Cao; Ying Yan; Qiao Ying; Tao Jiang; Ke Xu; Anhua Wu
Journal:  BMC Cancer       Date:  2010-08-10       Impact factor: 4.430

Review 7.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

8.  Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma.

Authors:  Wenna Shi; Lihui Su; Qianqian Li; Lidan Sun; Jing Lv; Jun Li; Baoquan Cheng
Journal:  Tumour Biol       Date:  2014-06-27

9.  TLR9 signaling promotes tumor progression of human lung cancer cell in vivo.

Authors:  Tao Ren; Lin Xu; Shuxian Jiao; Yanying Wang; Yingyun Cai; Yongjie Liang; Ya Zhou; Hong Zhou; Zhenke Wen
Journal:  Pathol Oncol Res       Date:  2009-03-25       Impact factor: 3.201

10.  Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment.

Authors:  Yusuke Sato; Yasufumi Goto; Norihiko Narita; Dave S B Hoon
Journal:  Cancer Microenviron       Date:  2009-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.